Cardiovascular Benefits of Anti-Obesity Drugs: Insights from Recent JACC Studies
Anti-Obesity Drugs and Cardiovascular Health
New studies in the Journal of the American College of Cardiology (JACC) reveal that anti-obesity medications like tirzepatide and semaglutide improve cardiovascular health beyond just weight loss. These findings were highlighted at the American Heart Association’s 2024 Scientific Sessions.
Dr. Harlan M. Krumholz stated, “These studies show the potential of GLP-1-based therapies to not only assist with weight loss but also enhance cardiac health. This offers hope for patients battling obesity and cardiovascular disease.”
Tirzepatide and Cardiac Structure
A secondary analysis of the SUMMIT trial focused on tirzepatide. This medication, approved for weight loss, was studied for its effects on patients with heart failure and obesity. The analysis involved 106 patients who underwent imaging to evaluate left ventricular mass and fat tissue around the heart.
Results indicated that tirzepatide reduced left ventricular mass by 11 grams and decreased paracardiac fat by 45 milliliters compared to placebo. These changes may help explain the reduction in heart failure events observed in the main SUMMIT trial.
Semaglutide’s Impact on Bypass Surgery Patients
Another analysis investigated semaglutide’s effects on patients with a history of coronary artery bypass surgery (CABG). Researchers enrolled 2,057 CABG patients, comparing them to 15,547 non-CABG patients.
Results showed that semaglutide consistently reduced major cardiovascular events more in CABG patients (2.3% risk reduction) compared to those without CABG (1% risk reduction). It also decreased the incidence of diabetes among CABG patients.
Lifestyle Interventions and Cardiac Biomarkers
The LookAHEAD trial analyzed how lifestyle changes affect cardiac biomarkers in Type 2 diabetes patients. The study focused on the impact of weight loss through lifestyle intervention.
Researchers found that this intervention led to significant reductions in high-sensitivity cardiac troponin T (hs-cTnT) after one and four years. They also noted that an increase in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at one year was not sustained at four years.
These changes in biomarkers are vital as high levels of NT-proBNP and hs-cTnT are linked to an increased risk of heart failure and cardiovascular disease.
References
-
“Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity,” by Subodh Verma et al., Journal of the American College of Cardiology, 2024.
- “Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes: LookAHEAD Cardiac Biomarker Ancillary Study,” by Kershaw V. Patel et al., Journal of the American College of Cardiology, 2024.